Physician profile
Nakia Murphy
NPI 1316788367
$4,277.70
in general payments reported to CMS, 2019-2025
48 companies · $3,547 in 2025
The $3,547 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $731 · 2025: $3,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,010 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.71 |
| Education | $267.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $347.19 | 2024-2025 | Rybrevant, Darzalex, Carvykti |
| Daiichi Sankyo INC. | $283.09 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $268.03 | 2025 | Enhertu, Calquence, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $252.99 | 2024-2025 | |
| Pfizer INC. | $229.99 | 2025 | |
| Sobi, INC | $209.91 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $209.21 | 2024-2025 | Breyanzi, Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $206.80 | 2024-2025 | |
| Incyte Corporation | $191.21 | 2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $134.34 | 2025 | Venclexta, Tecentriq, Polivy |
| Merck Sharp & Dohme LLC | $128.45 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genzyme Corporation | $124.94 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.07 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $107.90 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Caris Mpi, INC. | $99.77 | 2025 | Mi Cancer Seek |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakia Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.